Search Results - "ROMANOV, Vadim V"

Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion by Bishop, Michael R., Maziarz, Richard T., Waller, Edmund K., Jäger, Ulrich, Westin, Jason R., McGuirk, Joseph P., Fleury, Isabelle, Holte, Harald, Borchmann, Peter, del Corral, Christopher, Tiwari, Ranjan, Anak, Özlem, Awasthi, Rakesh, Pacaud, Lida, Romanov, Vadim V., Schuster, Stephen J.

“…Tisagenlecleucel demonstrated high rates of durable responses in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) in the…”
Get full text

Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial by Schuster, Stephen J., Maziarz, Richard T., Rusch, Elisha S., Li, Junlong, Signorovitch, James E., Romanov, Vadim V., Locke, Frederick L., Maloney, David G.

“…Chimeric antigen receptor T-cell (CAR-T) therapy yields durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)…”
Get full text

Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial by Maziarz, Richard T., Schuster, Stephen J., Romanov, Vadim V., Rusch, Elisha S., Li, Junlong, Signorovitch, James E., Maloney, David G., Locke, Frederick L.

“…Chimeric antigen receptor-T (CAR-T) cell therapy achieves durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL), but…”
Get full text

Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia by ROMANOV, Vadim V, JAMES, Christine H, SHERRINGTON, Paul D, PETTITT, Andrew R

“…p53 is the most frequently inactivated gene in human cancers, reflecting its pivotal role in maintaining genomic integrity. The present study was conducted to…”
Get full text

Consensus Grading of Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel on the JULIET Study by Schuster, Stephen J., Maziarz, Richard T., Ericson, Solveig G., Rusch, Elisha S., Signorovitch, James, Romanov, Vadim V., Locke, Frederick L., Maloney, David G.

“…Introduction: Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy achieves rapid and durable responses in patients with r/r DLBCL, although…”
Get full text

Safety and Efficacy of Tisagenlecleucel Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) and No Evidence of Active Disease Following Bridging Chemotherapy in the JULIET Trial by Bishop, Michael R., Maziarz, Richard Thomas T., Waller, Edmund K., del Corral, Christopher, Tiwari, Ranjan, Anak, Özlem, Awasthi, Rakesh, Romanov, Vadim V., Schuster, Stephen J.

“…INTRODUCTION It is unknown whether chimeric antigen receptor (CAR)-T cells expand or provide clinical benefit in patients (pts) without detectable disease…”
Get full text

Grading of Neurotoxicity in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study by Maziarz, Richard T., Schuster, Stephen J., Romanov, Vadim V., Rusch, Elisha S., Signorovitch, James, Ericson, Solveig G., Maloney, David G., Locke, Frederick L.

“…Introduction: CAR-T cell therapy has demonstrated prompt and durable clinical responses in patients with r/r DLBCL, but is associated with unique toxicities…”
Get full text